HER2 Testing: Towards a Brighter Future

Presented by

Dr. Sangeeta Desai, Dr. Suseela Kodandapani and Dr. Veena R

About this talk

This webinar, sponsored by Roche, provided valuable insights into the latest advances in HER2 diagnostics in breast cancer. Dr. Sangeeta Desai, Professor and Head at the Department of Pathology, Tata Memorial Centre, India a renowned expert with over three decades of experience and more than 250 research papers published, shared her knowledge on the HER2 FISH vs DISH assay and its crucial role in patient management. In addition, a panel discussion featuring Dr. Suseela Kodandapani and Dr. Veena R, along with Dr. Desai, provided a platform for the experts to discuss various unresolved issues and controversies in breast cancer diagnosis. Attendees also had the opportunity to participate in an open question session. The event was a great success, with over 400 registrations and 188 attending the live webinar. We extend our gratitude to our colleagues in the Indian affiliate, for organizing this insightful webinar. If you were unable to join on March 16, 2023, we invite you to take advantage of the opportunity to watch the recording and learn from the esteemed experts who participated in this event.
Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (64)
Subscribers (8669)
This series is brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.